Twelve weeks' sertraline and CBT in young people with anxiety disorders increases likelihood of no longer having the diagnosis compared with placebo or monotherapy, but residual symptoms remain

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish (US)
Pages (from-to)71
Number of pages1
JournalEvidence-Based Mental Health
Volume15
Issue number3
DOIs
StatePublished - Aug 2012

Fingerprint

Sertraline
Anxiety Disorders
Placebos

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

@article{1cbfc1ed019a4225a8c84d40aa9bfac1,
title = "Twelve weeks' sertraline and CBT in young people with anxiety disorders increases likelihood of no longer having the diagnosis compared with placebo or monotherapy, but residual symptoms remain",
author = "Betsy Kennard",
year = "2012",
month = "8",
doi = "10.1136/ebmental-2012-100729",
language = "English (US)",
volume = "15",
pages = "71",
journal = "Evidence-Based Mental Health",
issn = "1362-0347",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Twelve weeks' sertraline and CBT in young people with anxiety disorders increases likelihood of no longer having the diagnosis compared with placebo or monotherapy, but residual symptoms remain

AU - Kennard, Betsy

PY - 2012/8

Y1 - 2012/8

UR - http://www.scopus.com/inward/record.url?scp=84865189299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865189299&partnerID=8YFLogxK

U2 - 10.1136/ebmental-2012-100729

DO - 10.1136/ebmental-2012-100729

M3 - Article

VL - 15

SP - 71

JO - Evidence-Based Mental Health

JF - Evidence-Based Mental Health

SN - 1362-0347

IS - 3

ER -